Pfizer (PFE) Enterprise Value (2009 - 2026)
Pfizer (PFE) posted quarterly Enterprise Value of -$12.8 billion for Q1 2026, up 24.95% year-over-year from -$10.2 billion in Q1 2025, and up 3.95% quarter-over-quarter from -$13.3 billion in Q4 2025.
Pfizer (PFE) Enterprise Value (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Enterprise Value for 18 consecutive years, with -$12.8 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 24.95% year-over-year to -$12.8 billion; the TTM figure through Mar 2026 stood at -$12.8 billion (up 24.95% YoY), while the FY2025 annual figure was -$13.3 billion, up 34.12% from the prior year.
- Enterprise Value rose to -$12.8 billion in Q1 2026 per PFE's latest filing, from -$13.3 billion in the prior quarter.
- Across five years, Enterprise Value topped out at $249.0 million in Q3 2023 and bottomed at -$44.5 billion in Q3 2023.
- Historically, Enterprise Value has averaged -$16.1 billion across 5 years, with a median of -$13.3 billion in 2025.
- Annual changes were most pronounced in 2022 — Enterprise Value surged 100.77% — and 2024, when it slumped 3987.55%.
- Pfizer's Enterprise Value stood at -$22.5 billion in 2022, then surged by 44.76% to -$12.4 billion in 2023, then tumbled by 62.56% to -$20.2 billion in 2024, then jumped by 34.12% to -$13.3 billion in 2025, then increased by 3.95% to -$12.8 billion in 2026.
- Business Quant data shows PFE's Enterprise Value at -$12.8 billion in Q1 2026, -$13.3 billion in Q4 2025, and -$14.7 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | -20.76 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | -6.52 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -7.09 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | -7.69 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | -4.90 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | -13.99 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -3.26 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -11.40 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -4.80 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -6.96 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | -11.40 Bn |
| Mar 29, 2026 | -12.77 Bn |
| Dec 31, 2025 | -13.30 Bn |
| Sep 28, 2025 | -14.69 Bn |
| Jun 29, 2025 | -12.93 Bn |
| Mar 30, 2025 | -17.02 Bn |
| Dec 31, 2024 | -20.18 Bn |
| Sep 29, 2024 | -9.68 Bn |
| Jun 30, 2024 | -6.83 Bn |
| Mar 31, 2024 | -11.65 Bn |
| Dec 31, 2023 | -12.42 Bn |
| Sep 30, 2023 | 249.00 Mn |
| Jul 2, 2023 | -44.51 Bn |
| Apr 2, 2023 | -19.71 Bn |
| Dec 31, 2022 | -22.48 Bn |
| Sep 30, 2022 | 227.00 Mn |
| Jul 3, 2022 | -33.04 Bn |
| Apr 3, 2022 | -23.64 Bn |
| Dec 31, 2021 | -30.81 Bn |
| Oct 3, 2021 | -29.42 Bn |